PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has signed a contract with PCAS Group, a global industrial manufacturer of pharmaceutical active ingredients, for the production and supply of ABX464, ABIVAX’s drug candidate for the treatment of HIV. Under
![]()
↧